Sarcomi NTRK- riarrangiati : Immunoistochimica e ibridazione fluorescente in situ

Title

Code

Sarcomi NTRK-riarrangiati

Type

Osservazionale

Start Year

2024

Status

In Corso

Principal Investigator

051-6366035

stefania.cocchi@ior.it

Cocchi Stefania, MSc

Researcher

Anatomy and Pathological Histology

Operational unit that carry out the study

departmental simple unit

Anatomia e istologia patologica

Head

Gambarotti Marco, MD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. Sarcomi NTRK-riarrangiati

Thursday 11 April 2024, 12:03

PG0005707_2024_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

Sarcomi NTRK- riarrangiati : Immunoistochimica e ibridazione fluorescente in situ

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

Sarcomi NTRK- riarrangiati : Immunoistochimica e ibridazione fluorescente in situ

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in